Report Highlights
The global orphan drugs market should reach $248.2 billion by 2026 from $190.8 billion in 2021 at a compound annual growth rate (CAGR) of 5.4% for the forecast period of 2021 to 2026.
Report Includes
- 26 tables
- An updated review of the global markets for orphan drugs (ODs) within the healthcare industry
- Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of market size and revenue forecast for biological and non-biological orphan drugs, and corresponding market share analysis by product type, therapeutic category and geographic region
- Emphasis on the regulation of clinical trials on orphan designated drugs by leading regulatory authorities including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) of Japan
- Review of the current status and trends in clinical trials for the development of drugs in rare diseases among the three registries from the U.S., EU and Japan
- Discussion of successful orphan medicinal products, rising influence of pharmacogenomics in the ODs market, information on specific rare diseases for which orphan drugs exist
- Assessment of the most promising therapeutic areas in the industry and leading orphan drugs in these areas
- Highlights of the industry structure for orphan drugs, pricing and reimbursement policies, COVID-19 impact assessment and market share analysis of the top 20 manufacturers of orphan drugs
- Descriptive company profiles of the market leading participants, including AbbVie Inc., Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi-Aventis
Report Scope
The scope of this study includes orphan drugs used in the global pharmaceutical markets. This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry. The report also analyzes each submarket and its applications, projections and market shares. Technological issues include the latest trends and developments.
This report covers the U.S. and European markets, and emerging global markets such as India, Japan, China, Singapore, Taiwan, Korea, Canada, Brazil, Africa, Australia and New Zealand.
This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. In addition, this report provides an overview of the global orphan drugs market and its competitive landscape.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- AI Impact on Specialty Water Treatment Chemicals Market - BCC Pulse Report (AIT086A)
- Data Center Networking Technologies: Global Markets (IFT103C)
- Global GLP-1 Analogues Market (PHM289A)
- Elastomers: Applications and Global Markets (CHM056E)
- Biofuels: Global Markets (EGY064F)
Related Reports
2023 Pharmaceuticals Research Review
This Pharmaceutical Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making since the inception of BCC Research in 1971.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Antibody Drugs: Technologies and Global Markets
The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global GLP-1 Analogues Market
This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025–2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Immunotherapy Drugs: Global Markets
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
Global Artificial Intelligence (AI) in Clinical Trials Market
The global market for Artificial Intelligence (AI) in Clinical Trials was valued at $2 billion in 2024 and is estimated to increase from $2.4 billion in 2025 to reach $6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.
Brain Tumor Therapeutics: Global Markets to 2030
The report provides an analysis of brain tumor therapeutics and analyzes market trends. Using 2024 as the base year, the report provides estimated market data for 2025 through 2030. The market in this report is segmented by therapy type, patient age, end user, and region. The report covers regulatory scenarios, drivers, restraints, opportunities, and the market share for key companies.
Global Viral Vector Manufacturing Markets and Technologies Through 2030
The global market for viral vector manufacturing is expected to grow from $6.3 billion in 2025 and is projected to reach $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 24.6% during the forecast period of 2025 to 2030.
Top Trending Reports
Contract Manufacturing of Medical Devices: Global Markets
The global market for contract manufacturing of medical devices is estimated to grow from $96.4 billion in 2025 to reach $155.2 billion by 2030, at a compound annual growth rate (CAGR) of 10% from 2025 to 2030.
Bioprocess Filtration: Global Markets
The global market for bioprocess filtration is estimated to grow from $8.4 billion in 2025 to reach $15.6 billion by 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
Global Data Center Market
The global market for data centers is expected to grow from $418.2 billion in 2025 and is projected to reach $691.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2025 to 2030.
Biological Therapies for Cancer: Technologies and Global Markets
The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.
Immunotherapy Drugs: Global Markets
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
Report Highlights
The global orphan drug market totaled nearly $123 billion in 2014 and will continue to grow to reach nearly $191 billion by 2019, demonstrating a compound annual growth rate (CAGR) of 9.2% during the forecast period (2014 to 2019).
Report Includes
- An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence, advantages inherent in orphan drug designation, and future growth trends.
- Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Detailed discussion of successful orphan products.
- Detailed analysis of blockbuster orphan drugs.
- The rising influence of pharmacogenomics in the orphan drug market.
- A discussion of specific rare diseases for which orphan drugs exist.
- Analysis of the most promising therapeutic areas in the industry and leading orphan drugs in these areas.
- An outline of legislation and regulation, including public and private agencies involved in support and development.
- Technology trends analysis within the orphan drug market.
- Comprehensive company profiles of major players in the industry.
Report Highlights
The global market for orphan drugs reached nearly $86.1 billion in 2012. The market is expected to reach $112.1 billion in 2017 for a compound annual growth rate (CAGR) of 5.4%.
Report Includes
- An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence, advantages inherent in orphan drug designation, and future growth trends
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Detailed discussion of successful orphan products
- Detailed analysis of blockbuster orphan drugs
- The rising influence of pharmacogenomics in the orphan drug market
- A discussion of specific rare diseases for which orphan drugs exist
- Analysis of the most promising therapeutic areas in the industry and leading orphan drugs in these areas
- An outline of legislation and regulation, including public and private agencies involved in support and development
- Technology trends analysis within the orphan drug market
- Comprehensive company profiles of major players in the industry.
Report Highlights
- Worldwide, the orphan drug market reached $84.9 billion in 2009. The market is expected to grow at a compound annual growth rate (CAGR) of nearly 6% to reach $112.1 billion by 2014. The U.S. accounted for 51% of the market in 2009 and is expected to grow at a CAGR of 8.9% to reach $65.9 billion by 2014.
-
Biologic drugs accounted for a major share (64.3%) of the orphan drug market with sales of $54.6 billion in 2009, up from $51.4 billion in 2008. The size of the biologic orphan drug market is projected to grow at a 6.9% CAGR to reach $76.2 billion by 2014.
- Orphan drugs for the cancer sector generated the largest amount of revenues, $30.6 billion in 2009, accounting for 36% of the market. Revenues for cancer-related orphan drugs are expected to grow at a CAGR of 10% to reach $49.7 billion in 2014.
Report Highlights
-
The global orphan drugs market reached $58.7 billion in 2006, growing by 8% from $54.5 billion in 2005. It is expected to grow at a compounded annual growth rate (CAGR) of 7% to reach $81.8 billion by 2011.
-
Regionally, U.S. revenues in the market grew to $32.5 billion accounting for 55% of the market in 2006. The U.S. market is expected to grow at a CAGR of 8% to reach $47.8 billion by 2011.
-
Biologic drugs account for over 60% of the orphan drug market with sales of $35.3 billion in 2006, up from $30.2 billion in 2005. The market size of biologic orphan drugs is projected to grow at a 9% CAGR to reach $53.4 billion by 2011.
Report Highlights
-
The total worldwide market for orphan drugs, including sales for nonorphan applications, exceeded $28 billion in 2003.
-
This market is expected to rise at an AAGR (average annual growth rate) of 9.1% to reach $43.6 billion in 2008.
-
As a percentage of overall global drug sales, orphans are expected to increase their share from 7.0% in 2003 to 7.5% in 2008, as growth of the orphan market outpaces that of the total market.
-
As of mid-2003, 221 orphan drugs had been developed for the treatment of rare diseases affecting about 11 million patients.
-
Some orphan products have sales in excess of $1 billion annually.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More